`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________________
`
`WATSON LABORATORIES, INC.
`
`Petitioner,
`
`v.
`
`UNITED THERAPEUTICS CORPORATION
`Patent Owner.
`
`_____________________________
`
`Case IPR2017-01622
`Patent 9,339,507
`_____________________________
`
`DECLARATION OF DEFOREST MCDUFF, Ph.D.
`
`Mail Stop Patent Board
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Declaration of DeForest McDuff, Ph.D.
`
`1
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 1 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`I, DeForest McDuff, Ph.D., declare as follows:
`
`I.
`
`Introduction
`
`Qualifications
`
`1.
`
`I am a Partner at Insight Economics and an expert in applied business
`
`economics, with more than ten years of experience in consulting, finance, and
`
`economic research. I provide expert witness testimony and consulting in a variety
`
`of areas, including lost profits, reasonable royalties, unjust enrichment, commercial
`
`success, irreparable harm, finance, statistics, valuation, and business optimization.
`
`2.
`
`My expertise and experience span a variety of topics, including
`
`intellectual property, competition, business, antitrust, finance, labor, employment,
`
`and class action. My work spans the life sciences (including pharmaceuticals,
`
`biotechnology, diagnostics, and medical devices), electronics (including consumer
`
`electronics, semiconductors, computers, and telecommunications), and has
`
`included projects on a diverse range of other industries.
`
`3.
`
`I have significant experience evaluating the economics of the
`
`pharmaceuticals industry. I have provided expert analysis and consulting in over
`
`50 cases involving pharmaceuticals and related products, including evaluations of
`
`economic damages, competition, commercial success, irreparable harm, and other
`
`issues. I have evaluated a number of pharmaceutical product launches, both in a
`
`Declaration of DeForest McDuff, Ph.D.
`
`2
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 2 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`litigation setting and an advisory role, and have published articles and taught
`
`continuing legal education on pharmaceutical topics as well.
`
`4.
`
`I earned my Ph.D. in economics from Princeton University. At
`
`Princeton, I received a National Science Foundation Graduate Research Fellowship
`
`for academic research studying economic and statistical properties of housing
`
`markets and financial derivatives. I have published research in several peer-
`
`reviewed academic journals. I graduated summa cum laude with undergraduate
`
`degrees in economics and mathematics from the University of Maryland.
`
`5.
`
`My curriculum vitae, provided as Attachment A, contains more details
`
`on my background, education, experience, and expert testimony.
`
`Scope of Work
`
`6.
`
`In connection with my work on this matter, Insight Economics has
`
`been retained by Winston & Strawn LLP on behalf of Watson Laboratories, Inc.
`
`(“Watson”). Insight Economics is being compensated at a rate of $700 per hour
`
`for my work and at lower rates for time spent by others on my team. The
`
`compensation of Insight Economics is not dependent on the substance of my
`
`testimony or the outcome of this matter.
`
`7.
`
`For this declaration, I was asked to evaluate aspects of commercial
`
`success relating to U.S. Patent No. 9,339,507 (Ex. 1001) as it relates to Tyvaso
`
`(treprostinil). This declaration is a statement of my opinions in this matter and the
`
`Declaration of DeForest McDuff, Ph.D.
`
`3
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 3 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`basis and reasons for those opinions.1 In forming the opinions expressed in this
`
`declaration, I have relied upon my education, experience, and knowledge of the
`
`subjects discussed.
`
`II. Background
`
`Patent-at-issue
`
`8.
`
`I understand that the following patent is at issue in this IPR
`
`proceeding: 9,339,507 (“the ’507 patent” or “the patent-at-issue”).
`
`9.
`
`The ’507 patent, entitled “Treprostinil Administration by Inhalation,”
`
`was filed on May 11, 2012 and issued on May 17, 2016. I understand that the ’507
`
`patent has the following abstract:
`
`Treprostinil can be administered using a metered dose inhaler. Such
`
`administration provides a greater degree of autonomy to patients. Also
`
`disclosed are kits that include a metered dose inhaler containing a
`
`pharmaceutical formulation containing treprostinil.
`
`1
`
`This declaration reflects only my current opinions, which are subject to
`
`change based upon additional information, analysis, and/or opinions of other
`
`experts.
`
`Declaration of DeForest McDuff, Ph.D.
`
`4
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 4 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`Pulmonary hypertension
`
`10.
`
`Pulmonary hypertension (“PH”) is generally defined by high blood
`
`pressure in the lungs and the right side of the heart. This can occur when blood is
`
`not able to flow freely through arterioles in the lungs. Over time, the heart muscle
`
`weakens from the increased effort required to pump blood and may fail.
`
`Pulmonary arterial hypertension (“PAH”) is known as Group 1 PH, classified by
`
`the World Health Organization (“WHO”), and includes PH that is inherited, has no
`
`known cause, or is caused by certain drugs or conditions.2
`
`11.
`
`Patients diagnosed with PH have several treatment options, including
`
`medications and surgery. Treatment for PH includes anticoagulants, digoxin,
`
`diuretics, and calcium channel blockers (“CCB”), among others. Heart or lung
`
`transplants or open heart surgery may be warranted if drug therapy is not
`
`successful. For the treatment of PAH, in particular, approved pharmaceuticals
`
`2
`
`Ex. 1120: Mayo Clinic Website, Pulmonary hypertension, Overview,
`
`http://www.mayoclinic.org/diseases-conditions/pulmonary-
`
`hypertension/home/ovc-20197480 (accessed 3/22/2017).
`
`Ex. 1122: NIH Website; National Heart, Lung, and Blood Institute; Types of
`
`Pulmonary Hypertension, https://www.nhlbi.nih.gov/health/health-
`
`topics/topics/pah/types (accessed 5/16/2017).
`
`Declaration of DeForest McDuff, Ph.D.
`
`5
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 5 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`target one of three major biochemical pathways: (1) the endothelin pathway,
`
`targeted by endothelin receptor antagonists (“ERAs”); (2) the nitric oxide (“NO”)
`
`pathway, targeted by phosphodiesterase inhibitors (“PDE-5”) and soluble
`
`guanylate cyclase stimulators (“GCS”); and (3) the prostacyclin pathway, targeted
`
`by prostacyclin analogues and IP receptor antagonists.3
`
`Tyvaso (treprostinil)
`
`12.
`
`Tyvaso (treprostinil) is a prescription pharmaceutical product sold by
`
`UTC that is indicated for treatment of PAH in WHO Group 1 patients to improve
`
`exercise ability. Tyvaso was approved by the FDA on July 30, 2009. Tyvaso is
`
`available in a 0.6mg/mL solution for inhalation.4
`
`3
`
`Ex. 1120: Mayo Clinic Website, Pulmonary hypertension, Overview,
`
`http://www.mayoclinic.org/diseases-conditions/pulmonary-
`
`hypertension/home/ovc-20197480 (accessed 3/22/2017).
`
`Ex. 1083: Cowen and Company, “Therapeutic Categories Outlook,” 2/2017,
`
`at 2249-2250.
`
`4
`
`Ex. 1140: Tyvaso, FDA Label, 6/2016.
`
`Declaration of DeForest McDuff, Ph.D.
`
`6
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 6 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`III. Analysis of Commercial Success
`
`Overview
`
`13. Commercial success may provide objective evidence that a patent
`
`owner may use to indicate that a patent is not obvious based on the alleged
`
`commercial success of a product embodying the invention of the patent. I
`
`understand that commercial success can be relevant to the determination of a
`
`patent’s obviousness based on the presumption that an idea could have been
`
`brought to market sooner, in response to market forces, had it been obvious to
`
`persons skilled in the art. I further understand that evidence of commercial success
`
`may be relevant if there is a nexus between the alleged commercial success and the
`
`patentable features of the asserted claims. In other words, I understand that the
`
`patent owner must show that the commercial success is attributable to demand for
`
`Ex. 1120: Mayo Clinic Website, Pulmonary hypertension, Overview,
`
`http://www.mayoclinic.org/diseases-conditions/pulmonary-
`
`hypertension/home/ovc-20197480 (accessed 3/22/2017).
`
`Ex. 1096: FDA Website, FDA Approved Drug Products, Tyvaso,
`
`http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.p
`
`rocess&ApplNo=022387 (accessed 5/17/2017).
`
`Declaration of DeForest McDuff, Ph.D.
`
`7
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 7 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`the alleged benefits of the patented technology relative to demand resulting from
`
`other factors.
`
`14.
`
`For this declaration, I have been informed that United Therapeutics
`
`Corporation made a number of assertions related to the alleged commercial success
`
`of Tyvaso as a secondary consideration during the prosecution of the patent-at-
`
`issue, or related patents, with the USPTO.5 Upon review, I find that those
`
`assertions of commercial success are based on a skewed market definition (Section
`
`III.B) and flawed evaluation of nexus (Section III.C). In addition, my own
`
`evaluation of the alleged commercial success indicates only modest commercial
`
`performance of Tyvaso (Section III.D) and low or no economic relevance to
`
`obviousness of the patent-at-issue (Section III.E). These opinions are discussed in
`
`more detail below.
`
`Alleged commercial success based on a skewed market definition
`
`15.
`
`I understand that, during patent prosecution, the patent owner made a
`
`number of assertions of commercial success based on Tyvaso’s alleged market
`
`shares among U.S. inhaled prostacyclin drugs compared to Ventavis (iloprost). I
`
`understand that the patent owner claimed that Tyvaso earned “the majority of the
`
`5
`
`See, for example, Ex. 1161.
`
`Declaration of DeForest McDuff, Ph.D.
`
`8
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 8 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`US market for inhaled prostacyclins from Ventavis in a single year” and referenced
`
`the following chart:6
`
`16. However, this purported market share is among only the two inhaled
`
`products on the market, and is overstated and unrepresentative of competition in
`
`this market because it omits relevant competing products. Substantial evidence
`
`indicates competition between Tyvaso and non-inhaled PAH therapies, for
`
`example:
`
`a. UTC’s CEO stated on an earnings conference call (2010-Q2) that
`
`“Roughly speaking about 10% of the patients come on to Tyvaso
`
`actually from parenteral therapies. Either Remodulin or Flolan or
`
`the other generic parenteral therapies. Maybe a tad less than
`
`10%. About 20% of the patients, maybe a little bit more than
`
`6
`
`See, for example, Ex. 1161 at 9.
`
`Declaration of DeForest McDuff, Ph.D.
`
`9
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 9 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`20%, come on to our therapy from Ventavis, and then the
`
`majority, the large majority, around 70%, come on to our therapy
`
`after not really achieving the results desired with either oral or
`
`more commonly dual oral therapies. That is PDE5 plus an
`
`ETRA. So, that's pretty much as you recall the situation as we
`
`reported last year. The majority of patients are coming from the
`
`oral therapies rather than at the expense of Ventavis.”7
`
`b. UTC 10-Ks from 2009 to 2016 indicate that UTC products
`
`“compete with many approved products in the United States and
`
`the rest of the world,” including: Flolan, Veletri, generic
`
`epoprostenol; Ventavis and Ilomedin; Tracleer; Letairis; Revatio
`
`and generic sildenafil citrate; Opsumit; Adempas; Uptraiv; and
`
`drugs in current development. UTC’s 10-Ks discuss how
`
`various product attributes provide certain competitive advantages
`
`and disadvantages within the competition to treat PAH patients:
`
`i. 2009 to 2013 (Ex. 1151 at 21; Ex. 1152 at 22; Ex. 1153
`
`at 23-24; Ex. 1154 at 23-24; Ex. 1155 at 22-23): “The use
`
`7
`
`Ex. 1142: UTC, “Q2 2010 United Therapeutics Earnings Conference Call,”
`
`7/28/2010, at 4.
`
`Declaration of DeForest McDuff, Ph.D.
`
`10
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 10 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`of the available oral therapies and Tyvaso, either alone or
`
`in combination, could delay the need for infusion therapy
`
`for many patients. As a result, the success of other
`
`therapies in preventing disease progression affects our
`
`commercial products. Furthermore, the
`
`commercialization of generic forms of other approved
`
`PAH therapies and the development of new PAH
`
`therapies may exert downward pressure on the pricing of
`
`our products.”
`
`ii. 2014 to 2015 (Ex. 1156 at 20-21; Ex. 1157 at 20-21):
`
`“We anticipate that [Orenitram] will face competition
`
`with existing oral PAH therapies, and will be regarded as
`
`a less invasive and more convenient alternative therapy
`
`to Tyvaso and Remodulin. The use of available oral
`
`therapies could delay many patients’ need for inhaled or
`
`infused prostacyclin therapy. As a result, the availability
`
`of oral therapies affects demand for our inhaled and
`
`infused products.”
`
`iii. 2016 (Ex. 1158 at 19-20): “…[Orenitram] offers a less
`
`invasive and more convenient alternative therapy to
`
`Declaration of DeForest McDuff, Ph.D.
`
`11
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 11 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`Remodulin and Tyvaso. The use of available oral
`
`therapies could delay many patients' need for inhaled or
`
`infused prostacyclin therapy. As a result, the availability
`
`of oral therapies affects demand for our inhaled and
`
`infused products.”
`
`c.
`
`Third-party analysts:
`
`i. RBC Capital Markets (2011) reports Tyvaso’s market
`
`share as 7% in 2011 (compared to 13% for Remodulin,
`
`12% for Letairis, 50% for Tracleer, 2% for Adcirca, and
`
`16% for Revatio).8
`
`ii. Cowen and Company (2017) reports Tyvaso sales of just
`
`7.4% of major PAH drugs sales worldwide as of 2016.9
`
`17.
`
`In contrast to the majority share asserted by the patent owner,
`
`Tyvaso’s sales share as a fraction of competing PAH therapies shows more modest
`
`commercial performance. Based on sales data reported by competing companies,
`
`8
`
`Ex. 1135: RBC Capital Markets, “Untied Therapeutics Corp.,” 6/13/2011,
`
`at 7.
`
`9
`
`Ex. 1083: Cowen and Company, “Therapeutic Categories Outlook,” 2/2017,
`
`at 2248-2250. ($405 million for Tyvaso / $5,456 million total) = 7.4%.
`
`Declaration of DeForest McDuff, Ph.D.
`
`12
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 12 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`Tyvaso’s share of sales among competing PAH therapies has ranged from 0.7% in
`
`2009 up to a peak of 10.4% in 2013 and declining to 7.3% by 2016. See
`
`Attachment B-9.
`
`Alleged commercial success based on flawed evaluation of nexus
`
`18.
`
`I understand that, during patent prosecution, the patent owner made a
`
`number of assertions relating to nexus based upon “clinical advantages of Tyvaso®
`
`over Ventavis® [being] direct results of: a) dosing regimen of Tyvaso® compared
`
`to Ventavis®; and b) the pulsed ultrasonic nebulizer used with Tyvaso® compared
`
`to Ventavis®.”10 The patent owner also made assertions as to Tyvaso’s
`
`“substantially lower share” of sales representatives, at 25.0% share for Tyvaso and
`
`30.7% share for Ventavis.11
`
`19. Other than its uncited claim regarding Tyvaso sales representatives
`
`compared to Ventavis (which, contrary to patent owner’s assertions on market
`
`shares, appear to be calculated as shares of a broader PAH market definition),
`
`patent owner provides no analysis of other factors that may drive demand for
`
`Tyvaso. To my knowledge, patent owner provided no evaluation of other factors
`
`commonly evaluated in determining nexus, including actual marketing
`
`10
`
`11
`
`See, for example, Ex. 1162 at 9–11; Ex. 1163 at 16–18.
`
`See, for example, Ex. 1161 at 9.
`
`Declaration of DeForest McDuff, Ph.D.
`
`13
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 13 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`expenditures, marketing messages, pricing, or other attributes contributing to
`
`demand for Tyvaso, such as the treprostinil compound (e.g., Ex. 1019: U.S. Patent
`
`4,306,075 (“the ’075 patent”)) or the application of treprostinil to treating PAH
`
`(e.g., Ex. 1025: U.S. Patent No. 5,153,222 (“the ’222 patent”)). Without
`
`evaluating these factors, patent owner does not provide adequate basis to conclude
`
`that Tyvaso’s commercial performance is driven by the alleged innovative aspects
`
`of the patent-at-issue.
`
`20. With respect to specific comparisons between Tyvaso and Ventavis, I
`
`understand from the declaration of Dr. Maureen Donovan, Ph.D. (Ex. 1002 at
`
`¶ 247) that this difference derives primarily from differences between treprostinil
`
`and iloprost rather than any alleged innovative aspects of the patent-at-issue, and
`
`thus differences in commercial performance are largely attributable to the ’075
`
`patent and ’222 patent rather than the patent-at-issue. I understand from Dr.
`
`Donovan (Ex. 1002 at ¶ 247) that the less frequent treatment with Tyvaso relates to
`
`treprostinil’s longer half-life relative to iloprost rather than any differences in the
`
`way the Ventavis and Tyvaso are delivered via inhalation.
`
`21.
`
`Finally, patent owner’s own assertions appear to support the notion
`
`that Tyvaso sales were impacted by marketing. Tyvaso’s purported 25.0% share of
`
`sales representatives compared to a peak market share of just 10.4% indicates
`
`above-average marketing relative to competition (i.e., the share of marketing
`
`Declaration of DeForest McDuff, Ph.D.
`
`14
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 14 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`expenditures exceeding the share of revenues). It is difficult to assess further
`
`without the underlying analysis provided by patent owner.
`
`Tyvaso sales show only modest commercial performance
`
`22. Contrary to patent owner’s assertions, Tyvaso sales show only modest
`
`commercial performance, as evidenced by: (1) comparisons to pharmaceutical
`
`products generally, and (2) comparisons to competitor PAH products.
`
`23.
`
`First, Tyvaso’s annual sales ranging from $152 million to $470
`
`million are not exceptional or even above-average in the context of pharmaceutical
`
`product sales. For example, published research on pharmaceutical product sales
`
`indicates that Tyvaso sales are below average for the pharmaceutical industry:
`
`compared to Tyvaso’s peak annual sales to date of $470 million in 2015, peak
`
`annual sales based on published research (normalized to 2015 USD) are $3.6
`
`billion for top-decile drugs (top 10% of drugs), $1.3 billion for 2nd-decile drugs
`
`(80-89% percentiles), and $633 million for average drug sales. See Attachment
`
`B-2. Top-decile and 2nd-decile drugs tend to be the drivers of profitability in the
`
`pharmaceutical industry, whereas average drugs tend to be close to break-even in
`
`Declaration of DeForest McDuff, Ph.D.
`
`15
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 15 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`terms of economic profits that account for the economic costs of development.12 A
`
`comparison of Tyvaso sales to these benchmarks can be seen as follows (see
`
`Attachment B-3):
`
`12
`
`Ex. 1084: DiMasi, Joseph A. and Henry G. Grabowski (2012), “R&D Costs
`
`and Returns to New Drug Development: A Review of the Evidence,” in
`
`Patricia Danzen and Sean Nicholson, ed., The Oxford Handbook of the
`
`Economics of the Biopharmaceuticals Industry, New York: Oxford
`
`University Press, at 43 (“The search for these blockbuster drugs, typically
`
`“first in class” or “best in class” compounds, has been a key driver of R&D
`
`competition over the past several decades.”).
`
`Ex. 1113: Grabowski, Henry, John Vernon, and Joseph A. DiMasi (2002),
`
`“Returns on Research and Development for 1990s New Drug Introductions,”
`
`Pharmacoeconomics 20(3): 11–29, at 11, 17, 22-23.
`
`Declaration of DeForest McDuff, Ph.D.
`
`16
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 16 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`24.
`
`Second, as another point of comparison, Tyvaso sales are middle-of-
`
`the-pack relative to competing PAH treatments. In comparison to Tyvaso’s peak
`
`annual sales of $470 million in 2015, peak annual sales of competing PAH
`
`treatments include $1.7 billion for Tracleer (2011), $1.1 billion for
`
`Letairis/Volibris (2016), $844 million for Opsumit (2016, 4th year on the market),
`
`and $602 million for Remodulin (2016). See Attachments B-4 and B-5. A
`
`comparison of Tyvaso sales to competing PAH drugs can be seen as follows
`
`(normalized to 2015 USD, noting that Tyvaso sales have already peaked and
`
`started to decline as of 2015 but that other drugs may continue to have even higher
`
`peak sales beyond 2016—see Attachment B-6):
`
`25.
`
`In sum, patent owner provides limited information and no basis for
`
`comparison to conclude that Tyvaso was a “tremendous commercial success.” By
`
`Declaration of DeForest McDuff, Ph.D.
`
`17
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 17 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`contrast, an economic evaluation of Tyvaso sales in proper context are only modest
`
`by comparison and are not demonstrative of commercial success.
`
`Low or no economic relevance of alleged commercial success
`
`26. Contrary to patent owner’s assertions, there is actually low or no
`
`economics relevance of any alleged commercial success, for several reasons,
`
`including: (1) blocking patents and regulatory exclusivity, (2) UTC’s specialization
`
`in PAH, and (3) contributions of the patent-at-issue.
`
`Blocking patents and regulatory exclusivity
`27.
`First, early patents covering Tyvaso and marketing exclusivity granted
`
`by the FDA reduce the economic relevance of any alleged commercial success due
`
`to blocking disincentives. A blocking patent is one that effectively blocks others
`
`from making, selling, or using a product without use of the invention purportedly
`
`claimed in that patent. Courts have found that, in the presence of blocking patents
`
`and market exclusivity, the existence of commercial success provides little
`
`probative value on whether a claimed technology is obvious. For example, in
`
`Merck v. Teva, the Federal Circuit found that Merck’s ability to prevent market
`
`entry by others via blocking patents and statutory exclusivity weakened any
`
`probative value of commercial success in evaluating non-obviousness of the
`
`Declaration of DeForest McDuff, Ph.D.
`
`18
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 18 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`patent-at-issue.13 This makes sense, economically, since other entities would have
`
`strong disincentives not to develop technology that they would be blocked from
`
`utilizing or implementing in the marketplace.
`
`28.
`
`In the case of Tyvaso, there are several patents that have been alleged
`
`to cover Tyvaso before the patent-at-issue in this case (e.g., in the FDA Orange
`
`Book or described as relating to treprostinil more broadly14):
`
`a. U.S. Patent No. 4,306,075 provides the composition and
`
`production of stable prostacyclin analogs, including UT-15 (i.e.,
`
`treprostinil), with approximate priority in or around 1980 and
`
`issuing in December 1981.15
`
`13
`
`14
`
`15
`
`Ex. 1121: Merck& Co., Inc. v. Teva Pharmaceuticals USA, Inc., 395 F.3d
`
`1364, 1376–77 (Fed. Cir. 2005).
`
`Ex. 1085: FDA Orange Book, 2010, at ADA 189 of 197.
`
`Ex. 1086: FDA Orange Book, 2017, at ADA 229 of 237.
`
`Ex. 1019: Composition and Process, U.S. Patent No. 4,306,075 (filed
`
`12/22/1980, issued 12/15/1981).
`
`Declaration of DeForest McDuff, Ph.D.
`
`19
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 19 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`b. U.S. Patent No. 5,143,222 provides the use of treprostinil for
`
`pulmonary hypertension and congestive failure, with approximate
`
`priority in or around 1988 and issuing in October 1992.16
`
`c. U.S. Patent No. 6,521,212 provides methods for treating PAH via
`
`inhalation, with approximate priority in or around 1999 and
`
`issuing in February 2003.17
`
`d. U.S. Patent No. 6,756,033 provides methods for treating PAH via
`
`inhalation, with approximate priority in or around 1999 and
`
`issuing in June 2004.18
`
`16
`
`Ex. 1025: Method of Treating Pulmonary Hypertension with Benzidine
`
`Prostaglandins, U.S. Patent No. 5,153,222 (filed 6/14/1991, issued
`
`10/6/1992).
`
`17
`
`Ex. 1018: Method for Treating Peripheral Vascular Disease by
`
`Administering Benzindene Prostaglandins by Inhalation, U.S. Patent No.
`
`6,521,212 (filed 3/15/2000, issued 2/18/2003).
`
`18
`
`Ex. 1057: Method for Delivering Benzindene Prostaglandins by Inhalation,
`
`U.S. Patent No. 6,756,033 (filed 8/6/2002, issued 6/29/2004).
`
`Declaration of DeForest McDuff, Ph.D.
`
`20
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 20 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`29.
`
`In addition, UTC was granted orphan drug exclusivity of 7 years
`
`through July 2016, providing it with market exclusivity following launch in 2009.19
`
`30. Accordingly, UTC’s exclusive license to the ’075 and ’222 patents
`
`and its market exclusivity for Tyvaso provides strong disincentives for other
`
`companies to develop and commercialize the technology of the patent-at-issue,
`
`even if those alleged innovations had been obvious. Moreover, I am not aware of
`
`any evidence that a license to those patents was offered to or pursued by other
`
`companies, and thus they represent a disincentive for development. In other
`
`words, even if there were a compelling commercial opportunity to be inferred by
`
`the alleged commercial success of Tyvaso, that alleged success would not be
`
`economically relevant to obviousness of the patent-at-issue since other companies
`
`would have been blocked from commercializing those technologies.
`
`Limited Market Interest
`31.
`Second, as discussed, commercial success may be relevant to
`
`obviousness based on the idea that a product or technology may have been
`
`developed sooner, in response to market forces, had it been obvious. In the case of
`
`Tyvaso, UTC had unique specialization in developing PAH treatments (and
`
`particularly drugs utilizing treprostinil as an active ingredient) that would not have
`
`19
`
`Ex. 1152: UTC, Form 10-K, 2010, at 19, 24.
`
`Declaration of DeForest McDuff, Ph.D.
`
`21
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 21 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`been shared by the broader market. This further weakens any nexus and economic
`
`inference between the alleged commercial success and the patent-at-issue.
`
`32. UTC has a history of pursuing and focusing on PAH treatments,
`
`including Remodulin, Tyvaso, Adcirca, and Orenitram,20 and has a specialization
`
`in PAH that is not shared by the broader market. Additionally, I understand that
`
`UTC was founded and originally existed in response to the CEO seeking to find a
`
`cure for PAH for her daughter and her dissatisfaction with options available on the
`
`market.21 As of present day and dating back to approximate patent priority dates,
`
`there have been only a few other companies with PAH drugs on the market. See
`
`Attachment B-8.
`
`33. Additionally, the evidence suggests a limited commercial opportunity
`
`and lack of market-wide interest in developing an inhaled treprostinil product. For
`
`example, Tyvaso’s designation as an orphan drug (reserved for products with low
`
`commercial opportunity and/or fewer than 200,000 U.S. patients) indicates a
`
`20
`
`21
`
`Ex. 1158: UTC, Form 10-K, 2016, at 4.
`
`Ex. 1079: CNBC, “Highest Paid Female CEO: Race to Save My Daughter,”
`
`5/19/2015, http://www.cnbc.com/2015/05/19/highest-paid-female-ceo-race-
`
`to-save-my-daughter.html.
`
`Declaration of DeForest McDuff, Ph.D.
`
`22
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 22 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`limited economic opportunity.22 The limited opportunity is further confirmed by
`
`Pharmacia & Upjohn Company and Glaxo Wellcome Inc. licensing early
`
`treprostinil patents to UTC rather than seeking to develop their own products.23
`
`34.
`
`In other words, market-wide development of PAH drugs appears to
`
`have been limited, and other developers would not have UTC’s motivation,
`
`experience, and resources in developing PAH treatments. This provides yet
`
`another hurdle for market-wide incentives for development that, all else being
`
`equal, further limits any inference of non-obviousness from the alleged commercial
`
`success of Tyvaso.
`
`Contributions of the patent-at-issue
`35.
`Third, I am not aware of the patent owner providing an evaluation of
`
`the contributions of the patent-at-issue relative to earlier Tyvaso patents described
`
`above. Based on the opinions of Dr. Donovan (Ex. 1002 at ¶¶ 243–44, 246–47), I
`
`understand that the clinical contributions of alleged novel device and dosing
`
`regimen are limited and that, by contrast, the vast majority of the clinical benefit of
`
`Tyvaso comes from the treprostinil compound itself and the application of that
`
`compound to treating PAH. Accordingly, for the purpose of a nexus to the
`
`22
`
`23
`
`Ex. 1152: UTC, Form 10-K, 2010, at 8, 24.
`
`Ex. 1143: UTC, Form 10-K, 2000, at 6.
`
`Declaration of DeForest McDuff, Ph.D.
`
`23
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 23 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`commercial performance of Tyvaso, there is very weak nexus (if any at all) to the
`
`’507 patent.
`
`36. With respect to the claimed novelty of the patents, I understand from
`
`Dr. Donovan (Ex. 1002 at ¶¶ 242–46) that all of the alleged benefits over the prior
`
`art are were known from publicly available nebulizers, were in the prior art, and
`
`allowed for the claimed dosing regimen. Thus, the alleged benefits of the claimed
`
`invention are unrelated to any advantages over prior art. Further, I have seen no
`
`evidence (and have no reason to believe) that Tyvaso’s commercial performance
`
`would be any different if it used a different (nonclaimed) type of nebulizer or a
`
`different (nonclaimed) dosing regimen.
`
`37.
`
`Finally, as discussed, with respect to specific comparisons between
`
`Tyvaso and Ventavis, I understand from Dr. Donovan (Ex. 1002 at ¶ 247) that this
`
`difference derives primarily from differences between treprostinil and iloprost
`
`rather than any alleged innovative aspects of the patent-at-issue, and thus
`
`differences in commercial performance are largely attributable to the ’075 patent
`
`and ’222 patent rather than the patent-at-issue. I understand from Dr. Donovan
`
`(Ex. 1002 at ¶ 247) that the less frequent treatment with Tyvaso relates to
`
`treprostinil’s longer half-life relative to iloprost rather than any differences in the
`
`way the Ventavis and Tyvaso are delivered via inhalation.
`
`Declaration of DeForest McDuff, Ph.D.
`
`24
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 24 of 45
`
`
`
`HIGHLY CONFIDENTIAL
`
`IV.
`
`Signature
`
`38.
`
`I declare that my statements based on my knowledge are true and
`
`those based on information and belief I believe to be true. I made all my statements
`
`in this declaration with the knowledge that willful false statements and the like are
`
`punishable by fine, imprisonment or both pursuant to 18 U.S.C. 1001.
`
`39.
`
`I understand that this declaration is to be filed as evidence in a
`
`contested case before the Patent Trial and Appeal Board of the United States Patent
`
`and Trademark Office. I acknowledge that I may be subject to cross examination
`
`in the case and that cross examination will take place within the United States. If
`
`cross examination is required of me, I will appear for cross examination within the
`
`United States during the time allotted for cross examination.
`
`______________________________
`DeForest McDuff, Ph.D.
`June 21, 2017
`
`Declaration of DeForest McDuff, Ph.D.
`
`25
`
`WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1055, p. 25 of 45
`
`
`
`(cid:44)(cid:47)(cid:39)(cid:44)(cid:62)(cid:122)(cid:3)(cid:18)(cid:75)(cid:69)(cid:38)(cid:47)(cid:24)(cid:28)(cid:69)(cid:100)(cid:47)(cid:4)(cid:62)(cid:3)
`
`(cid:3)
`
`(cid:3)
`
`(cid:3)
`
`(cid:3)
`
`(cid:3)
`
`(cid:4)(cid:410)(cid:410)(cid:258)(cid:272)(cid:346)(cid:373)(cid:286)(cid:374)(cid:410)(cid:3)(cid:4)(cid:3)
`(cid:68)(cid:272)(cid:24)(cid:437)(cid:296)(cid:296)(cid:3)(cid:18)(cid:115)(cid:3)
`(cid:3)
`(cid:3)
`
`(cid:3)
`
`(cid:3)
`
`(cid:58)(cid:437)(cid:374)(cid:286)(cid:3)(cid:1006)(cid:1004)(cid:1005)(cid:1011)(cid:3)
`
`(cid:3)
`
`(cid:3) (cid:3) (cid:3)
`
`(cid:24)(cid:286)(cid:38)(cid:381)(cid:396)(cid:286)(cid:400)(cid:410)(cid:3)(cid:68)(cid:272)(cid:24)(cid:437)(cid:296)(cid:296)(cid:853)(cid:3)(cid:87)(cid:346)(cid:856)(cid:24)(cid:856)(cid:3)
`
`(cid:3) (cid:24)
`
`(cid:286)(cid:38)(cid